107 related articles for article (PubMed ID: 32054500)
1. Adverse event rates and economic burden associated with purine nucleoside analogs in patients with hairy cell leukemia: a US population-retrospective claims analysis.
Epperla N; Pavilack M; Olufade T; Bashyal R; Li J; Kabadi SM; Yuce H; Andritsos L
Orphanet J Rare Dis; 2020 Feb; 15(1):47. PubMed ID: 32054500
[TBL] [Abstract][Full Text] [Related]
2. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Hu R; Wei W; Mian A; Gonter-Aubin K; Kabel C; Mato A; Stephens DM; Hanlon A; Khajavian S; Shadman M; Brander D; Madanat Y; Park JH; Tallman M; Pinilla-Ibarz J; Hill BT
Eur J Haematol; 2022 May; 108(5):379-382. PubMed ID: 35043475
[TBL] [Abstract][Full Text] [Related]
5. Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Wang Y; Wang T; Yu Y; Wang Q; Yan Y; Li R; Sun Q; Xiong W; Lyu R; Yu Z; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
Ann Hematol; 2022 Jun; 101(6):1201-1210. PubMed ID: 35437610
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.
Divino V; Karve S; Gaughan A; DeKoven M; Gao G; Knopf KB; Lanasa MC
J Comp Eff Res; 2017 Sep; 6(6):497-508. PubMed ID: 28485619
[TBL] [Abstract][Full Text] [Related]
7. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.
Kabadi SM; Near A; Wada K; Burudpakdee C
Cancer Med; 2019 Dec; 8(17):7174-7185. PubMed ID: 31595715
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
[No Abstract] [Full Text] [Related]
10. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
12. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
13. Commercial claims costs related to health care resource use associated with a diagnosis of peanut allergy.
Shaker M; Chalil JM; Tran O; Vlahiotis A; Shah H; King T; Green TD; Greenhawt M
Ann Allergy Asthma Immunol; 2020 Apr; 124(4):357-365.e1. PubMed ID: 31954759
[TBL] [Abstract][Full Text] [Related]
14. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
Guest JF; Smith H; Sladkevicius E; Jackson G
Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
17. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
18. Purine analog toxicity in patients with hairy cell leukemia.
Tadmor T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():38-42. PubMed ID: 21463124
[TBL] [Abstract][Full Text] [Related]
19. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
20. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
